Secunderabad Chronicle

Glioblastoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

 Breaking News
  • No posts were found

Glioblastoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

May 10
20:04 2023
Glioblastoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Glioblastoma pipeline constitutes 100+ key companies continuously working towards developing 100+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Glioblastoma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

 

The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Glioblastoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years. 
  • Glioblastoma companies working in the treatment market are J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment 
  • Emerging Glioblastoma therapies such as – IN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.   
  • In January 2023, A clinical update from the ongoing Phase I trial investigating INB-200 in patients with newly diagnosed GBM was released by IN8bio, Inc., a clinical-stage biopharmaceutical firm researching novel gamma-delta T cell treatments, along with pipeline targets for 2023. In the first results from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM), all three patients outlived the median progression-free survival (PFS) of seven months, with two continued responses extending beyond 1.5 years and 1.2 years progression-free, respectively. Cohort 3 will be fully enrolled in the Phase I trial by the company, and it also intends to disclose more data and topline outcomes with longer-term follow-up
  • In September 2022, TCAN-2409 was given an orphan drug designation (ODD) by the European Medicines Agency (EMA) Committee for Orphan Medical Products for the purpose of treating glioma patients. In numerous ongoing clinical trials, CAN-2409 is being tested for high-grade gliomas, non-small cell lung cancer, pancreatic cancer, and prostate cancer

 

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight

 

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

  • JIN 001: J INTS BIO
  • CT 179: Curtana Pharmaceuticals
  • PRT3645: Prelude Therapeutics
  • TVB2640: Ascletis Pharma
  • Trabedersen: Oncotelic Therapeutics
  • Selinexor: Karyopharm Therapeutics
  • Onfekafuspalfa: Philogen
  • AZD1390: AstraZeneca
  • YTX7739: Yumanity Therapeutics
  • CD200AR L: OX2 Therapeutics
  • ADI-PEG 20: Polaris Group
  • CM93: Crimson Biopharm
  • Berubicin: CNS Pharmaceuticals
  • SurVaxM: MimiVax
  • BPM31510: Berg, LLC
  • ASC40: Ascletis
  • Enzastaurin: Denovo Biopharma
  • Marizomib: Celgene Corporation

 

Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Glioblastoma Pipeline Therapeutics Assessment

  • Glioblastoma Assessment by Product Type
  • Glioblastoma By Stage and Product Type
  • Glioblastoma Assessment by Route of Administration
  • Glioblastoma By Stage and Route of Administration
  • Glioblastoma Assessment by Molecule Type
  • Glioblastoma by Stage and Molecule Type

 

DelveInsight’s Glioblastoma Report covers around 100+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies

 

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are – NeOnc Technologies, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Cellectar Biosciences, OncoSynergy, Inc, WPD Pharmaceuticals, CellabMED, Alpheus Medical, Inc., Eli Lilly and Company, Xynomic Pharmaceuticals, Inc., Celldex Therapeutics, Sumitomo Pharma Oncology, Inc., Curis, Plus Therapeutics, Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee’s Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, Istari Oncology, Angiochem, Epitopoietic Research Corporation, Oblato, Inc., Novartis, Candel Therapeutics, Chimerix, Onxeo SA, SonALAsense, Kintara Therapeutics, Kazia Therapeutics, VBI Vaccines, Lantern Pharma, and others.

 

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
  • Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Glioblastoma drugs and therapies

 

Glioblastoma Pipeline Market Drivers

  • Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure• Demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

 

Glioblastoma Pipeline Market Barriers

  • However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

 

Scope of Glioblastoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Glioblastoma Companies: J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
  • Key Glioblastoma Therapies: IN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
  • Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
  • Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers 

 

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials

 

Table of Contents

1

Glioblastoma Report Introduction

2

Glioblastoma Executive Summary

3

Glioblastoma Overview

4

Glioblastoma- Analytical Perspective In-depth Commercial Assessment

5

Glioblastoma Pipeline Therapeutics

6

Glioblastoma Late Stage Products (Phase II/III)

7

Glioblastoma Mid Stage Products (Phase II)

8

Glioblastoma Early Stage Products (Phase I)

9

Glioblastoma Preclinical Stage Products

10

Glioblastoma Therapeutics Assessment

11

Glioblastoma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Glioblastoma Key Companies

14

Glioblastoma Key Products

15

Glioblastoma Unmet Needs

16 

Glioblastoma Market Drivers and Barriers

17

Glioblastoma Future Perspectives and Conclusion

18

Glioblastoma Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles

Recent Posts

Improve Work Tasks by Pairing INNOCN 27 Inch Monitor 27G1H with the Spacetop

Read Full Article